Polynovo Ltd
Company Profile
Business description
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Contact
320 Lorimer Street
Unit 2
Port MelbourneVIC3207
AUST: +61 386814050
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2025
Employees
8
Stocks News & Analysis
stocks
Microsoft earnings: Strength in cloud, guidance mixed
stocks
Chart of the week: Small caps lagging
stocks
An impending merger just raised our fair value for this ASX retail giant
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,379.70 | 42.40 | -0.50% |
CAC 40 | 7,409.11 | 58.74 | 0.80% |
DAX 40 | 19,254.97 | 177.43 | 0.93% |
Dow JONES (US) | 42,052.19 | 288.73 | 0.69% |
FTSE 100 | 8,177.15 | 67.05 | 0.83% |
HKSE | 20,506.43 | 189.10 | 0.93% |
NASDAQ | 18,239.92 | 144.77 | 0.80% |
Nikkei 225 | 38,053.67 | 1,027.58 | -2.63% |
NZX 50 Index | 12,559.28 | 79.62 | -0.63% |
S&P 500 | 5,728.80 | 23.35 | 0.41% |
S&P/ASX 200 | 8,118.80 | 41.20 | -0.50% |
SSE Composite Index | 3,272.01 | 7.81 | -0.24% |